Ireland
--:--IST
Starting soon Phase 2

Study of the Effects of Rimonabant on Functional Recovery in Subacute Stroke Patients

NCT07941479 · tracked via the Priya Life Science Spain tracker
Phase
Phase 2
Started
2026-11-30
Last updated
2026-11-17

Condition(s) studied

Subacute Stroke

Investigational drug(s) / intervention(s)

Rimonabant →Placebo

Rimonabant: Rimonabant 5 mg administered orally as one orally disintegrating tablet (ODT) once daily for 90 consecutive days.

Placebo: Participants will receive one matching placebo orally disintegrating tablet (ODT) once daily for 90 consecutive days. The placebo contains no rimonabant.

Study summary

The main goal of this clinical trial is to assess the effect of rimonabantim on the functional independence in adults who have recently experienced a stroke. The study will enroll 80 participants aged 18 to 75 years who had an stroke 30 to 90 days before enrolment and who have difficulties performing daily activities.

Participants will receive either rimonabant (5 mg) or placebo (a look-alike tablet that contains no drug) once daily for 90 days. Neither the participants nor the investigators will know which treatment is being given.The study will also help to learn about the safety of rimonabant.

Eligibility

Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: * Age between 18 and 75 years. * Between 30 days and 3 months (30 - 90 days) since the stroke. * mRS score between 2 and 4. * BI score ≤ 70 at screening. * Capacity to provide informed consent. Exclusion Criteria: * High suicide risk assessed by C-SSRS. * History of severe psychiatric disorders, major depression or prior suicide attempts. * Treatment with anticoagulants or strong CYP3A4 inhibitors or inducers (inhibitors such as ketoconazole, itraconazole, ritonavir, telithromycin, clarithromycin, or nefazodone, and inducers such as rifampicin, phenytoin, phenobarbital, carbamazepine, or St. John's Wort). * Patients with a history of ischemic or haemorrhagic stroke resulting in a residual mRS \> 1, or with a pre-existing mRS \> 1 due to other medical conditions. * BMI \> 40 kg/m². * Pregnancy or breastfeeding. * Fertile men or women who cannot guarantee the use of highly effective contraceptive methods, as defined by the European HMA-CTFG guidelines at least 45 days after the last dose of rimonabant -i.e., those with a failure rate of less than 1 % per year when used consistently and correctly (CTFG, 2020). * Uncontrolled hypothyroidism, or a history of severe bone, liver, or kidney disease. * Known allergy to rimonabant or any of the excipients used. * Participation in another clinical trial within the month prior to enrolment. * Any other condition that, in the opinion of the investigator, makes the subject's participation in the study unrecommended, such as severe heart failure or uncontrolled diabetes.

Primary outcome measure(s)

  • Barthel Index (BI) — Baseline and end of follow-up (day 135)
    The BI measures the ability to perform activities of daily living. It consists on a ten-item scale that examine functions such as feeding, bathing, continence, mobility and dressing.

Trial sites (6)

FacilityCityRegionStatus
Hospital Universitario de Albacete Albacete Albacete
Institut Guttmann Badalona Barcelona
Jiménez Lucena S.L. (CLÍNICA I+TÚ) Córdoba Córdoba
Hospital Los Madroños Brunete Madrid
Hospital Clínico San Carlos (HCSC) Madrid Madrid
Hospital Universitario La Paz Madrid Madrid
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07941479 on ClinicalTrials.gov ↗ ← All trials in Spain